Manufacturer with High Purity and Stable Quality
Commercial Supply Imatinib Mesylate (CAS: 220127-57-1) and Related Intermediates:
Imatinib Mesylate CAS: 220127-57-1
N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine CAS: 152460-09-8
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea CAS: 152460-10-1
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS: 106261-49-8
| Chemical Name |
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride |
| Synonyms |
Imatinib Mesylate Intermediate |
| CAS Number |
106261-49-8 |
| CAT Number |
RF-PI229 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C13H20Cl2N2O2 |
| Molecular Weight |
307.22 |
| Solubility in Water |
Soluble |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Almost White Powder to Crystal |
| Purity / Analysis Method |
≥98.0% (HPLC) |
| Loss on Drying |
≤0.50% |
| Residue on ignition |
≤0.50% |
| Total Impurities |
≤2.0% |
| Maximum Single Impurity |
≤1.0% |
| Test Standard |
Enterprise Standard |
| Usage |
Pharmaceutical Intermediate of Imatinib Mesylate (CAS: 220127-57-1) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS: 106261-49-8) with high quality.
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS: 106261-49-8) is an intermediate typically in the synthesis of Imatinib Mesylate (CAS: 220127-57-1).
Imatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib mesylate binds up this crucial kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib mesylate have been used in the treatment of various cancers.
Imatinib mesylate is A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It's a potent and selective v-Abl tyrosine kinase inhibitor (IC50 = 38 nM). Also inhibits PDGFR and c-kit. Exhibits selectivity for v-Abl over a panel of other tyrosine and serine/threonine protein kinases. Selectively inhibits PDGF-stimulated growth of v-abl-transformed PB-3 cells and v-sis-transformed BALB/c 3T3 cells in vitro. Exhibits antitumor effects in mice bearing AMuLV or BABL/c 3T3 v-sis cells. Inhibits replication of SARS-CoV and MERS-CoV in vitro (EC50 values are 9.823 and 17.689 μM, respectively).